Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant ± Lapatinib ± Aromatase Inhibitor in Metastatic Breast Cancer
NCT00688194Phase 3Unknown
- Sponsor
- Gruppo Italiano Mammella
- Start
- May 2008
- Primary completion
- May 2013
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of lapatinib, anastrozole, exemestane and letrozole in breast cancer (4 arms), sponsored by Gruppo Italiano Mammella. Primary endpoint: Progression-Free Survival. Status: unknown.
02
Drugs
lapatinibanastrozoleexemestaneletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00688194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00688194.